Gilead BGR study
340B contract pharmacy arrangements rose 252% for grantee covered entities between 2017 to 2022 compared to 194% for hospitals, a new drug company-funded study found.

340B Grantees Need More Scrutiny as Drug Margins Rise, Gilead-funded Study Says

Health centers and other federal grantees’ 340B savings and how they use them need more scrutiny, as these covered entities account for a large chunk of total 340B drug sales and their margins are keeping pace with those of hospitals, a new drug company-funded study says.

The study was funded by drug maker Gilead Sciences, whose products include treatments for HIV/AIDS and hepatitis often prescribed by 340B grantee entities. Berkeley Research Group, the company that established drug industry 340B contract pharmacy policy administrator 340B ESP, conducted the study released on May 22. Gilead Chair and CEO Daniel O’Day is PhRMA’s board chair-elect. 

Health centers and other federal grantees’ 340B savings and how they use them need more scrutiny, as these covered entities account for a large chunk of total 340B drug sales and their margins are keeping pace with those of hospitals, […]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer